Show simple item record

dc.contributor.authorValderhaug, Vibeke Devold
dc.contributor.authorHeiney, Kristine
dc.contributor.authorHuse Ramstad, Ola
dc.contributor.authorBråthen, Geir
dc.contributor.authorKuan, Wei-Li
dc.contributor.authorNichele, Stefano
dc.contributor.authorSandvig, Axel
dc.contributor.authorSandvig, Ioanna
dc.date.accessioned2021-03-24T09:53:00Z
dc.date.available2021-03-24T09:53:00Z
dc.date.created2020-05-06T12:19:43Z
dc.date.issued2020
dc.identifier.citationBioRxiv. 2020, .en_US
dc.identifier.issn0362-4331
dc.identifier.urihttps://hdl.handle.net/11250/2735243
dc.description.abstractA patterned spread of proteinopathy represents a common characteristic of many neurodegenerative diseases. In Parkinson’s disease (PD), misfolded forms of alpha-synuclein proteins aggregate and accumulate in hallmark pathological inclusions termed Lewy bodies and Lewy neurites, which seems to affect selectively vulnerable neuronal populations and propagate within interconnected neuronal networks. Research findings suggest that these proteinopathic inclusions are present at very early timepoints in disease development, even before strong behavioural symptoms of dysfunction arise, but that these underlying pathologies might be masked by homeostatic processes working to maintain the function of the degenerating neural circuits. This study investigates whether inducing the PD-related alpha-synuclein pathology in engineered human neural networks can be associated with changes in network function, and particularly with network criticality states. Self-organised criticality represents the critical point between resilience against perturbation and adaptational flexibility, which appears to be a functional trait in self-organising neural networks, both in vitro and in vivo. By monitoring the developing neural network activity through the use of multielectrode arrays (MEAs) for a period of three weeks following proteinopathy induction, we show that although this developing pathology is not clearly manifest in standard measurements of network function, it may be discerned by differences in network criticality states.en_US
dc.language.isoengen_US
dc.publisherBioRxiven_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleCriticality as a measure of developing proteinopathy in engineered human neural networksen_US
dc.typeJournal articleen_US
dc.description.versionsubmittedVersionen_US
dc.source.pagenumber22en_US
dc.source.journalBioRxiven_US
dc.identifier.doihttps://doi.org/10.1101/2020.05.03.074666
dc.identifier.cristin1809648
dc.relation.projectNorges forskningsråd: 270961en_US
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: xen_US
dc.description.localcodeThis article is a preprint and has not been certified by peer review.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal